Phosphatidylinositol-specific phospholipase C (PI-PLC)

Phosphatidylinositol-specific phospholipase C (PI-PLC) represents a diverse family of eukaryotic intracellular enzymes that serve as pivotal effectors in cell signaling pathways. These enzymes catalyze the hydrolysis of the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into two potent second messengers: inositol 1,4,5-trisphosphate (IP3), which triggers calcium release from the endoplasmic reticulum, and diacylglycerol (DAG), which activates protein kinase C. In mammals, the PI-PLC family consists of 13 isoforms classified into six subfamilies (beta, gamma, delta, epsilon, zeta, and eta), each regulated by distinct mechanisms such as G-protein coupling or tyrosine kinase activation. Dysregulation of these enzymes is implicated in various pathologies, including cancer progression, cardiovascular diseases like cardiac hypertrophy, and inflammatory conditions such as Graves' orbitopathy. While PI-PLC is a highly attractive therapeutic target, drug development is complicated by its ubiquitous presence and fundamental role in cellular homeostasis, which increases the risk of systemic toxicity. Current pharmacological research focuses on developing isoform-specific inhibitors and modulators, such as the experimental compounds U73122 and Edelfosine, to selectively disrupt disease-associated signaling axes.

Other names

Phosphoinositide phospholipase CPLC1-phosphatidylinositol 4,5-bisphosphate phosphodiesterasePhosphoinositide-specific phospholipase CPI-PLC

Hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), leading to intracellular calcium mobilization and activation of protein kinase C (PKC) signaling cascades.